The spread of artemisinin-resistant Plasmodium falciparum in the Greater Mekong subregion: a molecular epidemiology observational study
- PMID: 28161569
- PMCID: PMC5406483
- DOI: 10.1016/S1473-3099(17)30048-8
The spread of artemisinin-resistant Plasmodium falciparum in the Greater Mekong subregion: a molecular epidemiology observational study
Erratum in
-
Corrections.Lancet Infect Dis. 2017 May;17(5):475. doi: 10.1016/S1473-3099(17)30180-9. Epub 2017 Apr 4. Lancet Infect Dis. 2017. PMID: 28389198 Free PMC article. No abstract available.
Abstract
Background: Evidence suggests that the PfKelch13 mutations that confer artemisinin resistance in falciparum malaria have multiple independent origins across the Greater Mekong subregion, which has motivated a regional malaria elimination agenda. We aimed to use molecular genotyping to assess antimalarial drug resistance selection and spread in the Greater Mekong subregion.
Methods: In this observational study, we tested Plasmodium falciparum isolates from Myanmar, northeastern Thailand, southern Laos, and western Cambodia for PfKelch13 mutations and for Pfplasmepsin2 gene amplification (indicating piperaquine resistance). We collected blood spots from patients with microscopy or rapid test confirmed uncomplicated falciparum malaria. We used microsatellite genotyping to assess genetic relatedness.
Findings: As part of studies on the epidemiology of artemisinin-resistant malaria between Jan 1, 2008, and Dec 31, 2015, we collected 434 isolates. In 2014-15, a single long PfKelch13 C580Y haplotype (-50 to +31·5 kb) lineage, which emerged in western Cambodia in 2008, was detected in 65 of 88 isolates from northeastern Thailand, 86 of 111 isolates from southern Laos, and 14 of 14 isolates from western Cambodia, signifying a hard transnational selective sweep. Pfplasmepsin2 amplification occurred only within this lineage, and by 2015 these closely related parasites were found in ten of the 14 isolates from Cambodia and 15 of 15 isolates from northeastern Thailand. C580Y mutated parasites from Myanmar had a different genetic origin.
Interpretation: Our results suggest that the dominant artemisinin-resistant P falciparum C580Y lineage probably arose in western Cambodia and then spread to Thailand and Laos, outcompeting other parasites and acquiring piperaquine resistance. The emergence and spread of fit artemisinin-resistant P falciparum parasite lineages, which then acquire partner drug resistance across the Greater Mekong subregion, threatens regional malaria control and elimination goals. Elimination of falciparum malaria from this region should be accelerated while available antimalarial drugs still remain effective.
Funding: The Wellcome Trust and the Bill and Melinda Gates Foundation.
Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license. Published by Elsevier Ltd.. All rights reserved.
Figures


Comment in
-
Evidence of a hard selective sweep for artemisinin resistant Plasmodium falciparum.Lancet Infect Dis. 2017 May;17(5):462-463. doi: 10.1016/S1473-3099(17)30056-7. Epub 2017 Feb 2. Lancet Infect Dis. 2017. PMID: 28161568 No abstract available.
Similar articles
-
Determinants of dihydroartemisinin-piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study.Lancet Infect Dis. 2019 Sep;19(9):952-961. doi: 10.1016/S1473-3099(19)30391-3. Epub 2019 Jul 22. Lancet Infect Dis. 2019. PMID: 31345710 Free PMC article. Clinical Trial.
-
Molecular epidemiology of resistance to antimalarial drugs in the Greater Mekong subregion: an observational study.Lancet Infect Dis. 2020 Dec;20(12):1470-1480. doi: 10.1016/S1473-3099(20)30228-0. Epub 2020 Jul 14. Lancet Infect Dis. 2020. PMID: 32679084 Free PMC article.
-
Evolution and expansion of multidrug-resistant malaria in southeast Asia: a genomic epidemiology study.Lancet Infect Dis. 2019 Sep;19(9):943-951. doi: 10.1016/S1473-3099(19)30392-5. Epub 2019 Jul 22. Lancet Infect Dis. 2019. PMID: 31345709 Free PMC article.
-
Geographic expansion of artemisinin resistance.J Travel Med. 2019 Jun 1;26(4):taz030. doi: 10.1093/jtm/taz030. J Travel Med. 2019. PMID: 30995310 Review.
-
Importance of kelch 13 C580Y mutation in the studies of artemisinin resistance in Plasmodium falciparum in Greater Mekong Subregion.J Microbiol Immunol Infect. 2020 Oct;53(5):676-681. doi: 10.1016/j.jmii.2019.07.006. Epub 2019 Sep 10. J Microbiol Immunol Infect. 2020. PMID: 31563454 Review.
Cited by
-
Naturally Acquired Kelch13 Mutations in Plasmodium falciparum Strains Modulate In Vitro Ring-Stage Artemisinin-Based Drug Tolerance and Parasite Survival in Response to Hyperoxia.Microbiol Spectr. 2022 Oct 26;10(5):e0128221. doi: 10.1128/spectrum.01282-21. Epub 2022 Sep 12. Microbiol Spectr. 2022. PMID: 36094220 Free PMC article.
-
Sharing public health data and information across borders: lessons from Southeast Asia.Global Health. 2018 Sep 29;14(1):94. doi: 10.1186/s12992-018-0415-0. Global Health. 2018. PMID: 30268139 Free PMC article.
-
The resistome and genomic reconnaissance in the age of malaria elimination.Dis Model Mech. 2019 Dec 19;12(12):dmm040717. doi: 10.1242/dmm.040717. Dis Model Mech. 2019. PMID: 31874839 Free PMC article. Review.
-
How to defuse malaria's ticking time bomb.Nature. 2018 Jul;559(7715):458-465. doi: 10.1038/d41586-018-05772-z. Nature. 2018. PMID: 30046090 No abstract available.
-
Monitoring of efficacy, tolerability and safety of artemether-lumefantrine and artesunate-amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Lambaréné, Gabon: an open-label clinical trial.Malar J. 2019 Dec 16;18(1):424. doi: 10.1186/s12936-019-3015-4. Malar J. 2019. PMID: 31842893 Free PMC article. Clinical Trial.
References
-
- WHO. Guidelines for the Treatment of Malaria, 3rd edn. Geneva, 2015.
-
- White NJ. Can new treatment developments combat resistance in malaria? Expert Opin Pharmacother. 2016;17:1303–1307. - PubMed
-
- Spring MD, Lin JT, Manning JE. Dihydroartemisinin-piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study. Lancet Infect Dis. 2015;15:683–691. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials